The impact of omeprazole on mycophenolate pharmacokinetics in kidney transplant recipients
- Author:
Mohamed S. ABDELHALIM
1
;
Ahmed S. KENAWY
;
Heba H. EL DEMELLAWY
;
Amany A. AZOUZ
;
Sarah S. ALGHANEM
;
Torki AL-OTAIBI
;
Osama GHEITH
;
Mohamed Abd ELMONEM
;
Mohammed K. AFIFI
;
Raghda R. S. HUSSEIN
Author Information
- Publication Type:Original Article
- From:Kidney Research and Clinical Practice 2020;39(4):479-486
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:The absorption rates of mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS) may be influenced by the concomitant use of omeprazole.
Methods:One hundred kidney transplant patients were recruited during their outpatient visits, including 50 on MMF and 50 on EC-MPS. At the clinic, a predose mycophenolic acid (MPA) sample (C0) was collected; subsequently, the participants received the proton-pump inhibitor omeprazole along with either MMF or EC-MPS. Two more blood samples were collected at 1.5 and 3.5 hours and used to estimate an area under the curve (AUC) from zero to 12 hours [AUC (0-12)].
Results:The mean number of months after transplant was 92 months. The median AUC (0-12) and C0 results were 62.2 mg·h/L and 2.0 mg/L for the MMF group and 71.9 mg·h/L and 1.8 mg/L for the EC-MPS group (P = 0.160 and 0.225, respectively). Interestingly, 54% of the MMF group and 62% of the EC-MPS group showed AUCs above the target values. The correlation between MPA C0 and the predicted AUC was poor in both groups.
Conclusion:Omeprazole can be safely co-administered with either MMF or EC-MPS, as it did not compromise the MPA exposure. Unexpectedly, however, a high percentage of patients presented MPA AUCs exceeding the target value, highlighting the importance of periodically assessing MPA level.
